StockNews.com lowered shares of Camden Property Trust (NYSE:CPT – Free Report) from a hold rating to a sell rating in a report published on Friday.
Several other brokerages have also recently issued reports on CPT. Piper Sandler upped their price objective on Camden Property Trust from $110.00 to $128.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Wedbush boosted their target price on shares of Camden Property Trust from $118.00 to $131.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Wells Fargo & Company raised shares of Camden Property Trust from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $104.00 to $127.00 in a report on Monday, August 26th. Scotiabank boosted their price objective on Camden Property Trust from $125.00 to $132.00 and gave the stock a “sector perform” rating in a research note on Monday, September 16th. Finally, Evercore ISI boosted their target price on Camden Property Trust from $116.00 to $118.00 and gave the company an “in-line” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $122.03.
Get Our Latest Analysis on CPT
Camden Property Trust Trading Up 1.9 %
Camden Property Trust Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Thursday, October 17th. Shareholders of record on Monday, September 30th were paid a $1.03 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $4.12 annualized dividend and a yield of 3.55%. Camden Property Trust’s dividend payout ratio (DPR) is 130.38%.
Hedge Funds Weigh In On Camden Property Trust
A number of large investors have recently made changes to their positions in CPT. Centersquare Investment Management LLC increased its stake in Camden Property Trust by 64.2% during the 1st quarter. Centersquare Investment Management LLC now owns 2,296,741 shares of the real estate investment trust’s stock valued at $228,939,000 after purchasing an additional 898,398 shares in the last quarter. Duquesne Family Office LLC acquired a new position in shares of Camden Property Trust in the 2nd quarter valued at $63,056,000. Robeco Institutional Asset Management B.V. raised its stake in Camden Property Trust by 4,254.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 341,810 shares of the real estate investment trust’s stock worth $42,224,000 after acquiring an additional 333,961 shares during the last quarter. Vanguard Group Inc. lifted its position in Camden Property Trust by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 17,291,878 shares of the real estate investment trust’s stock worth $1,701,521,000 after acquiring an additional 289,425 shares during the period. Finally, American Century Companies Inc. grew its stake in Camden Property Trust by 690.1% during the 2nd quarter. American Century Companies Inc. now owns 248,533 shares of the real estate investment trust’s stock valued at $27,117,000 after purchasing an additional 217,076 shares during the last quarter. 97.22% of the stock is owned by institutional investors and hedge funds.
Camden Property Trust Company Profile
Camden Property Trust, an S&P 500 Company, is a real estate company primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. Camden owns and operates 172 properties containing 58,250 apartment homes across the United States.
Featured Stories
- Five stocks we like better than Camden Property Trust
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Intel: Is Now the Time to Be Brave?Â
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Insider Trades May Not Tell You What You Think
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Camden Property Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Camden Property Trust and related companies with MarketBeat.com's FREE daily email newsletter.